A Phase I, Single Center Trial of Adoptive Immunotherapy With T-reg Adoptive Cell Transfer (TRACT) to Prevent Rejection in Living Donor Kidney Transplant Recipients

Trial Profile

A Phase I, Single Center Trial of Adoptive Immunotherapy With T-reg Adoptive Cell Transfer (TRACT) to Prevent Rejection in Living Donor Kidney Transplant Recipients

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs CD4+ CD25+ Treg cells (Primary)
  • Indications Renal transplant rejection
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 29 Jul 2016 Results of this trial were presented at the American Transplant Congress 2016, according to a Tract Therapeutics media release.
    • 24 Jul 2015 New trial record
    • 22 Jul 2015 According to a Tract Therapeutics media release, safety data from this trial were presented at the American Transplant Congress Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top